FOLH1 and prostate carcinoma: To date, 177Lu radionuclide therapy is mainly used to treat patients with neuro-endocrine tumours (NET) targeting SSTRs [90], and patients with metastatic castration resistant prostate cancer targeting prostate-specific membrane antigen (PSMA), which is expressed at high levels on the surface of prostate cancer cells (radioligand therapy, RTL) [91].